This is a scientific update with no near-term commercial or regulatory catalyst. Monitor for any subsequent announcement of a larger controlled trial in Alzheimer's, which would be the next meaningful de-risking event. The existing 20-F (April 2026) showed strong revenue growth of 27% to $52.2M — that fundamental trajectory is the primary driver, not this pilot data.
Price Chart
Executive Summary
BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and Neurology showing Deep TMS achieved an 83.3% response rate and 50% remission rate for depressive symptoms in patients with comorbid MDD and early-stage Alzheimer's disease, alongside measurable neurophysiological changes. This is an early-stage, hypothesis-generating result in a new indication (Alzheimer's) for which Deep TMS is not FDA-cleared, requiring additional controlled trials before any commercial pathway. The filing is a routine scientific update with no financial data, no regulatory submission, and no change to the company's existing three FDA-cleared indications, making it a modest positive signal for the platform's optionality but not a near-term catalyst.
Key Facts
- Pilot study (n=12) published in peer-reviewed Journal of Geriatric Psychiatry and Neurology
- 83.3% response rate and 50% remission rate for depressive symptoms in patients with MDD and early-stage Alzheimer's
- Deep TMS is NOT FDA-cleared for Alzheimer's disease; additional controlled research required
- Study used H1 and H7 coils; observed QEEG changes in delta power and alpha coherence
- No financial figures, guidance, or regulatory milestones reported in this filing
Financial Impact
No financial impact reported; pilot study is early-stage research with no revenue or cost implications disclosed
Risk Factors
- Pilot study has very small sample size (n=12) and no control arm, limiting generalizability
- Deep TMS is not FDA-cleared for Alzheimer's; path to clearance requires large, expensive pivotal trials with uncertain outcomes
- Historical performance on BWAY shows mixed T+20 outcomes with 50% win rate; prior high-score reports (7-8) underperformed, suggesting caution on overreacting to pipeline news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005912 |
| Document: f6k_090626.htm | 0001171843-26-005912 |
| Document: 0001171843-26-005912-index-headers.html | 0001171843-26-005912 |
| Document: 0001171843-26-005912-index.html | 0001171843-26-005912 |
| Document: 0001171843-26-005912.txt | 0001171843-26-005912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access